

Erratum to: The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline

Mark E. Linskey · David W. Andrews · Anthony L. Asher · Stuart H. Burri ·
Douglas Kondziolka · Paula D. Robinson · Mario Ammirati · Charles S. Cobbs ·
Laurie E. Gaspar · Jay S. Loeffler · Michael McDermott · Minesh P. Mehta ·
Tom Mikkelsen · Jeffrey J. Olson · Nina A. Paleologos · Roy A. Patchell ·
Timothy C. Ryken · Steven N. Kalkanis

Published online: 1 January 2010
© Springer Science+Business Media, LLC. 2009

Erratum to: J Neurooncol DOI 10.1007/s11060-009-0073-4

In the Abstract of the original publication, the level numbers indicated for the **Recommendations** regarding **SRS plus WBRT vs. WBRT alone** were incorrect. The correct level numbers are shown below.

Recommendations

SRS plus WBRT vs. WBRT alone

Level 1 Single-dose SRS along with WBRT leads to significantly longer patient survival compared with WBRT

The online version of the original article can be found under doi:[10.1007/s11060-009-0073-4](https://doi.org/10.1007/s11060-009-0073-4).

M. E. Linskey
Department of Neurosurgery, University of California-Irvine
Medical Center, Orange, CA, USA

D. W. Andrews
Department of Neurosurgery, Thomas Jefferson University,
Philadelphia, PA, USA

A. L. Asher
Department of Neurosurgery, Carolina Neurosurgery and Spine
Associates, Charlotte, NC, USA

S. H. Burri
Department of Radiation Oncology, Carolinas Medical Center,
Charlotte, NC, USA

D. Kondziolka
Department of Neurological Surgery, University of Pittsburgh
Medical Center, Pittsburgh, PA, USA

P. D. Robinson
McMaster University Evidence-based Practice Center, Hamilton,
ON, Canada

alone for patients with single metastatic brain tumors who have a KPS ≥ 70 .

Level 1 Single-dose SRS along with WBRT is superior in terms of local tumor control and maintaining functional status when compared to WBRT alone for patients with 1–4 metastatic brain tumors who have a KPS ≥ 70 .

Level 2 Single-dose SRS along with WBRT may lead to significantly longer patient survival than WBRT alone for patients with 2–3 metastatic brain tumors.

Level 3 There is class III evidence demonstrating that single-dose SRS along with WBRT is superior to WBRT alone for improving patient survival for patients with single or multiple brain metastases and a KPS < 70 .

M. Ammirati
Department of Neurosurgery, Ohio State University Medical
Center, Columbus, OH, USA

C. S. Cobbs
Department of Neurosciences, California Pacific Medical Center,
San Francisco, CA, USA

L. E. Gaspar
Department of Radiation Oncology, University of Colorado-Denver, Denver, CO, USA

J. S. Loeffler
Department of Radiation Oncology, Massachusetts General
Hospital, Boston, MA, USA

M. McDermott
Department of Neurosurgery, University of California
San Francisco, San Francisco, CA, USA

M. P. Mehta
Department of Human Oncology, University of Wisconsin
School of Public Health and Medicine, Madison, WI, USA

T. Mikkelsen · S. N. Kalkanis (✉)
Department of Neurology, Henry Ford Health System, 2799
West Grand Blvd, K-11, Detroit, MI 48202, USA
e-mail: kalkanis@neuro.hfh.edu

J. J. Olson
Department of Neurosurgery, Emory University School of
Medicine, Atlanta, GA, USA

N. A. Paleologos
Department of Neurology, Northshore University Health
System, Evanston, IL, USA

R. A. Patchell
Department of Neurology, Barrow Neurological Institute,
Phoenix, AZ, USA

T. C. Ryken
Department of Neurosurgery, Iowa Spine and Brain Institute,
Iowa City, IA, USA